Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
If approved, WELIREG would be the first and only oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor available for these patients in the European Union
Positive opinion granted based on data from the Phase 2 LITESPARK-004 trial and the Phase 3 LITESPARK-005 trial
The private equity firm circling Boots the Chemist's parent company is lining up financing from a syndicate of banks for a prospective $10bn-plus takeover deal.
Sky News has learnt that Sycamore Partners is arranging debt funding for a deal to buy Walgreens Boots Alliance, with Bank of America, JP Morgan and Wells Fargo among those understood to be in the frame.
If completed, a takeover would see Sycamore take one of the biggest providers of retail pharmacy services in the US and Britain private.
It would almost certainly pave the way for an onward sale of Boots, which employs more than 50,000 people in Britain and trades from about 1,900 shops.
Earlier this week, Sky News reported that Stefano Pessina, the arch-dealmaker who has led a string of major deals involving Boots over the last two decades, could end up as the majority-owner of one of Britain's most prominent retailers.
Sycamore would be expected to sell both Boots and VillageMD, the doctor-staffed chain of clinics, according to one industry source.
Walgreens had already been considering options for its interest in VillageMD.
The Wall Street Journal revealed on Tuesday that Sycamore Partners was in talks to buy WBA, which has seen its market value plummet to less than $8bn in recent months before rebounding on news of the talks.
Mr Pessina, who holds a roughly-17% stake in WBA, may end up as the principal owner of Boots depending on how the deal with Sycamore is structured.
WBA has orchestrated, and terminated, at least two processes to explore a sale of Boots in the last few years, deciding that offers from parties including Apollo Global Management did not offer sufficient value.
Boots recently appointed a new boss after Seb James, its long-serving managing director, resigned for a new role in the healthcare industry.
The company's heritage dates back to John Boot opening a herbal remedies store in Nottingham in 1849.
It opened its 1000th UK store in 1933.
Sycamore declined to comment.
https://news.sky.com/story/boots-bidder-lines-up-banks-to-finance-10bn-takeover-deal-13272772
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission (EC), which has the authority to approve medicines in the European Union (EU), will review the CHMP’s recommendation and is expected to make a final decision on the marketing authorization application (MAA) in the following months.
Rep. Alexandria Ocasio-Cortez sparked controversy Thursday with her remarks on the fatal shooting of UnitedHealthcare CEO Brian Thompson when she suggested that those shocked by people’s lack of sympathy toward the slain CEO simply don’t understand Americans’ frustration with the health care system.
“This is not to say that an act of violence is justified, but I think for anyone who is confused or shocked or appalled, they need to understand that people interpret and feel and experience denied claims as an act of violence against them,” the congresswoman told CBS News’ Jaala Brown on Thursday.
Ocasio-Cortez (D-NY) maintained that systemic inequality is the real problem. “Health care in this country has gotten to such a depraved state that people are living with things they should never have to live with. And this is not to say and this is not to participate in that glorification, but we need to understand that extreme levels of inequality in the United States yield high degrees of social instability,” she said.
AOC’s comments drew a slew of backlash from those who are fed up with those excusing the cold-blooded murder, lovers of the accused killer, Luigi Mangione, and posters across the Big Apple warning other CEOs that they’re next on the hit list.
“Violence is never the answer, full stop. Rationalizing such actions only deepens divisions and detracts from real solutions. The focus should be on reforming the system, not excusing tragedy. Leadership should aim to heal, not fan the flames of desperation,” another user said on X, slamming AOC’s language.
The lefty rep’s comments come as Luigi copycats have come out of the woodwork, including one Florida mother who was arrested Tuesday after allegedly making threats on a call to BlueCross BlueShield regarding the denial of a recent medical insurance claim.he murder of Thompson, which garnered national attention for days leading up to Mangione’s arrest, has drawn fanfare and downright obsession over the ex-Ivy Leaguer from a wealthy Maryland family.
Mangione is accused of fatally shooting Thompson as the 50-year-old CEO walked to the Hilton hotel on Sixth Avenue, where UnitedHealthcare’s parent company, UnitedHealth Group, was holding its annual investor conference on Dec. 4.
The University of Pennsylvania grad led police on a five-day manhunt that ended when he was taken into custody at a Pennsylvania McDonald’s after an employee recognized him and called police.
He was found in possession of a manifesto-type document that mentioned UnitedHealthcare and accused health insurance companies of corporate greed.
